Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Zogenix Took a Tumble Today

By Maxx Chatsko - Feb 7, 2020 at 11:49AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite reports of positive late-stage results for an important drug candidate, Wall Street was hoping for more.

What happened

Shares of Zogenix (ZGNX) fell more than 32% today after the company reported positive top-line results from an important phase 3 study evaluating Fintepla as a treatment for a rare childhood form of epilepsy called Lennox-Gastaut syndrome (LGS). While the drug candidate achieved a statistically significant reduction in the rate of seizures compared to the placebo -- which was the primary endpoint of the study -- investors weren't impressed by the magnitude of the difference. 

In the LGS study, the highest dose of Fintepla reduced the number of monthly seizures by 26.5% compared to baseline, while individuals taking the placebo achieved a reduction of only 7.8%. The difference of 18.7% was statistically significant. However, as highlighted by Endpoints News, the difference in reductions of monthly seizures between the highest dose of Fintepla and the placebo in an earlier study of Dravet syndrome was 70%. Dravet syndrome is another form of epilepsy. 

As of 10:52 a.m. EST, the pharma stock had settled to a 31.3% loss.

A woman checking her phone in surprise.

Image source: Getty Images.

So what

It's one thing for investors to hope that the magnitude of seizure reductions enabled by Fintepla would be equivalent from Dravet syndrome to LGS. It's another thing to realistically expect equivalency. 

Put another way, the results of the two trials don't make for an apples-to-apples comparison. The age of individuals enrolled in each study was different. And although both Dravet syndrome and LGS are characterized by seizures, they don't have the exact same pathology. In fact, the difference in monthly seizure rate reductions between the two studies provides a very helpful clue for researchers studying the nuance of each disease. That's how science works.

Of course, Wall Street works a bit differently. Analyst projections for the drug candidate's eventual market share potential, pricing potential, and peak sales potential in LGS were based in part on the expected reduction in monthly seizures. Considering the high bar set by Fintepla in Dravet syndrome, analysts were likely expecting better results in LGS than what were reported this week. A smaller-than-expected reduction in monthly seizures negatively impacts those financial models and reduces expectations for Fintepla.

Now what

Based on the top-line results, Fintepla has decent odds of earning marketing approval in LGS. The drug candidate met the primary endpoint of the phase 3 study and achieved statistically significant improvements on multiple secondary endpoints. Whether it earns approval and grabs sufficient market share will take years to know, but Wall Street isn't wasting time resetting expectations for the drug candidate and Zogenix. Investors should wait for a more complete picture of the results before getting too carried away.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zogenix, Inc. Stock Quote
Zogenix, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.